Jefferies Downgrades Johnson & Johnson to a “Hold” Rating (JNJ)

Pharmaceutical goods manufacturing company, Johnson & Johnson(JNJ) has been downgraded to a “Hold” by Jefferies on Monday.

The firm has downgraded JNJ from a “Buy” to a “Hold,” and has lowered its price target from $78 to $75. This price target suggests a 6.8% increase over the stock’s current price of $69.87.

An analyst from the firm commented, “we upgraded J&J to Buy in June on the back of the re-engineered financing of the Synthes merger, which was highly accretive in our view. We looked for the shares to re-rate to a 10-15% market premium from the 1% discount at the time. Most of this move has occurred now and with the MD&D day postponed and reimbursement pressures intensifying we see the shares as fairly valued.”

Johnson & Johnson shares were mostly flat during premarket trading Monday. The stock is up 6.54% YTD.

The Bottom Line
We have been recommending shares of Johnson & Johnson (JNJ) since Apr.27, 2012, when the stock was trading at $64.75. The company has a 3.49% dividend yield, based on Friday’s closing stock price of $69.87.

Johnson & Johnson(JNJ) is a “Recommended” dividend stock at this time, holding a DARS™ Rating of 3.5 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here